These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

7642 related articles for article (PubMed ID: 1703292)

  • 1. [Locoregional use of TNF (tumor necrosis factor) in the treatment of malignant melanoma].
    Lejeune F
    Pathol Biol (Paris); 1990 Oct; 38(8):883-4. PubMed ID: 1703292
    [No Abstract]   [Full Text] [Related]  

  • 2. [Isolated hyperthermic perfusion of extremities in malignant melanoma with melphalan and tumor necrosis factor].
    Kettelhack C; Hohenberger P; Schlag PM
    Langenbecks Arch Chir Suppl Kongressbd; 1996; 113():127-9. PubMed ID: 9101810
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Isolated limb perfusion with high-dose tumor necrosis factor for extremity melanoma and sarcoma.
    Fraker DL; Alexander HR
    Important Adv Oncol; 1994; ():179-92. PubMed ID: 8206489
    [No Abstract]   [Full Text] [Related]  

  • 4. [Isolated extremity perfusion with tumor necrosis factor and melphalan.An option for treatment of satellite or in transit metastasis of malignant melanoma].
    Schlag PM; Kettelhack C
    Hautarzt; 1995 May; 46(5):361-2. PubMed ID: 7607905
    [No Abstract]   [Full Text] [Related]  

  • 5. Isolated limb perfusion for unresectable melanoma of the extremities.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
    Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VWF release and platelet aggregation in human melanoma after perfusion with TNF alpha.
    Renard N; Nooijen PT; Schalkwijk L; De Waal RM; Eggermont AM; Liénard D; Kroon BB; Lejeune FJ; Ruiter DJ
    J Pathol; 1995 Jul; 176(3):279-87. PubMed ID: 7674090
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale for using TNF alpha and chemotherapy in regional therapy of melanoma.
    Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Rosenkaimer F; Gérain J; Klaase J; Kroon B; Vanderveken J; Schmitz P
    J Cell Biochem; 1994 Sep; 56(1):52-61. PubMed ID: 7806592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Value of isolation-perfusion of the limbs in melanomas and sarcomas].
    Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Kroon B
    Ann Chir; 1995; 49(1):9-12. PubMed ID: 7741477
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of in-transit metastases from cutaneous melanoma by isolation perfusion with tumour necrosis factor-alpha (TNF-alpha), melphalan and interferon-gamma (IFN-gamma). Dose-finding experience at the National Cancer Institute of Milan.
    Vaglini M; Santinami M; Manzi R; Inglese MG; Santoro N; Persiani L; Belli F
    Melanoma Res; 1994 Mar; 4 Suppl 1():35-8. PubMed ID: 8038594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
    Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
    Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hyperthermic isolated limb perfusion with tumor necrosis factor alone for melanoma.
    Posner MC; Lienard D; Lejeune FJ; Rosenfelder D; Kirkwood J
    Cancer J Sci Am; 1995; 1(4):274-80. PubMed ID: 9166488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hyperthermic isolation limb perfusion with TNFalpha in the treatment of in-transit melanoma metastasis.
    Di Filippo F; Rossi CR; Santinami M; Cavaliere F; Garinei R; Anzà M; Perri P; Botti C; Di Angelo P; Pasqualoni R; Di Filippo S
    In Vivo; 2006; 20(6A):739-42. PubMed ID: 17203758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020.
    Cornett WR; McCall LM; Petersen RP; Ross MI; Briele HA; Noyes RD; Sussman JJ; Kraybill WG; Kane JM; Alexander HR; Lee JE; Mansfield PF; Pingpank JF; Winchester DJ; White RL; Chadaram V; Herndon JE; Fraker DL; Tyler DS;
    J Clin Oncol; 2006 Sep; 24(25):4196-201. PubMed ID: 16943537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical experience with high-dose tumor necrosis factor alpha in regional therapy of advanced melanoma.
    Lejeune F; Liénard D; Eggermont A; Schraffordt Koops H; Kroon B; Gérain J; Rosenkaimer F; Schmitz P
    Circ Shock; 1994 Aug; 43(4):191-7. PubMed ID: 7895325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccinia virus.
    Gnant MF; Berger AC; Huang J; Puhlmann M; Wu PC; Merino MJ; Bartlett DL; Alexander HR; Libutti SK
    Cancer Res; 1999 Sep; 59(18):4668-74. PubMed ID: 10493523
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rationale and clinical status of 41.8 degrees C systemic hyperthermia tumor necrosis factor, and melphalan for neoplastic disease.
    Robins HI; D'Oleire F; Grosen E; Spriggs D
    Anticancer Res; 1997; 17(4B):2891-4. PubMed ID: 9329556
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complete response of melanoma-in-transit metastasis after isolated limb perfusion with tumor necrosis factor alpha and melphalan without massive tumor necrosis: a clinical and histopathological study of the delayed-type reaction pattern.
    Nooijen PT; Eggermont AM; Schalkwijk L; Henzen-Logmans S; de Waal RM; Ruiter DJ
    Cancer Res; 1998 Nov; 58(21):4880-7. PubMed ID: 9809994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of repeat isolated limb perfusions with tumor necrosis factor alpha and melphalan for multiple in-transit metastases in patients with prior isolated limb perfusion failure.
    Grünhagen DJ; van Etten B; Brunstein F; Graveland WJ; van Geel AN; de Wilt JH; Eggermont AM
    Ann Surg Oncol; 2005 Aug; 12(8):609-15. PubMed ID: 15968498
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration.
    Curnis F; Sacchi A; Corti A
    J Clin Invest; 2002 Aug; 110(4):475-82. PubMed ID: 12189241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human recombinant alpha- and gamma-interferons enhance the cytotoxic properties of tumor necrosis factor on human melanoma.
    Bregman MD; Meyskens FL
    J Biol Response Mod; 1988 Aug; 7(4):384-9. PubMed ID: 3139842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 383.